| h-075f1f02 | Brain Insulin Resistance with Glucose Transporter Dysfunction | 0.60 | 0.50 | GLUT3/GLUT4 | proposed | 2026-04-03 | SDA-2026-04-02-gap-v2-5d0e3052 |
| h-var-9da3ee8550 | Closed-loop tACS targeting EC-II PV interneurons to enhance perisomatic inhibiti | 0.60 | 0.72 | PVALB | promoted | 2026-04-07 | SDA-2026-04-03-26abc5e5f9f2 |
| h-1dc6387ca9 | Exosomal α-Synuclein as an Interneuronal Propagation Vector in Parkinson's Disea | 0.59 | 0.75 | RAB27A | proposed | 2026-04-26 | legacy-pre-pipeline-import-v1 |
| h-793f9f273d | Temporal Decoupling of CSF p-tau217 Normalization from Amyloid PET Negativity Cr | 0.59 | 0.58 | NA - Biomarker validation hypothesis | proposed | 2026-04-25 | |
| h-3c73c503dd | Aβ42 oligomers drive TDP-43 phosphorylation at s409/410 through CDK5/p25 activat | 0.59 | 0.62 | CDK5R1 (p25 regulatory subunit) | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062202-094b44bf |
| h-57e8f4db75 | Aβ-induced downregulation of circPDS5B derepresses TDP-43 mRNA translation in li | 0.59 | 0.50 | circPDS5B (hsa_circ_0083342) / TARDBP | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062202-094b44bf |
| h-05b8894a | Netrin-1 Gradient Restoration | 0.59 | 0.20 | NTN1 | debated | 2026-04-02 | sda-2026-04-01-gap-005 |
| h-18a0fcc6 | VCP-Mediated Autophagy Enhancement | 0.59 | 0.49 | VCP | archived | 2026-04-02 | SDA-2026-04-04-gap-tau-prop-20260402003221 |
| h-822ed52f | GFAP Perivascular Redistribution (End-Feet Retraction) as True BBB Dysfunction B | 0.59 | 0.18 | GFAP | proposed | 2026-04-26 | SDA-2026-04-26-gap-bbb-permeability-biomarker-20260426 |
| h-0636e675 | NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Complement Amplification | 0.59 | 0.60 | NAMPT, SIRT1 | promoted | 2026-04-17 | SDA-2026-04-16-gap-20260416-133111 |
| h-gwas-ptk2b-endocyt | Tau-trafficking GWAS loci define a druggable PTK2B endocytosis-kinase axis in AD | 0.59 | 0.58 | PTK2B/BIN1/PICALM | proposed | 2026-04-26 | |
| h-2648ab06ce | Stratified falsifiers should govern Methodology challenge: notebook 'Astrocyte r | 0.59 | 0.54 | challenge | proposed | 2026-04-28 | SDA-2026-04-27-gap-methodol-20260427-035148-9ab1842d |
| h-87b29d2a9d | Stratified falsifiers should govern Methodology challenge: notebook 'Mitochondri | 0.59 | 0.54 | challenge | proposed | 2026-04-28 | SDA-2026-04-27-gap-methodol-20260427-035148-7b3b3df4 |
| h-f8bd14f311 | Stratified falsifiers should govern AD Master Plan preregistration: TREM2 | 0.59 | 0.54 | AD | proposed | 2026-04-28 | AD-MASTER-PLAN-TREM2-20260428030753 |
| h-9ba0d309d9 | Stratified falsifiers should govern AD Master Plan preregistration: APOE | 0.59 | 0.54 | AD | proposed | 2026-04-28 | AD-MASTER-PLAN-APOE-20260428030754 |
| h-1179b3cc89 | Stratified falsifiers should govern AD Master Plan preregistration: BDNF | 0.59 | 0.54 | AD | proposed | 2026-04-28 | AD-MASTER-PLAN-BDNF-20260428030755 |
| h-87754d6a4a | Stratified falsifiers should govern AD Master Plan preregistration: GFAP | 0.59 | 0.54 | AD | proposed | 2026-04-28 | AD-MASTER-PLAN-GFAP-20260428030756 |
| h-d3b4afec85 | Stratified falsifiers should govern AD Master Plan preregistration: LRP1 | 0.59 | 0.54 | AD | proposed | 2026-04-28 | AD-MASTER-PLAN-LRP1-20260428030757 |
| h-1664ae69a6 | Stratified falsifiers should govern Microglial Priming as Upstream Causal Node A | 0.59 | 0.54 | CX3CR1 | proposed | 2026-04-28 | SDA-2026-04-28-microglial-priming-causal-nd |
| h-b6c9f53f86 | Stratified falsifiers should govern Causal Discovery Benchmark: SciDEX vs LLM Ba | 0.59 | 0.54 | causal discovery | proposed | 2026-04-28 | SDA-causal-benchmark-20260428-035713 |
| h-aba0219737 | Stratified falsifiers should govern Methodology challenge: notebook 'Mitochondri | 0.59 | 0.54 | challenge | proposed | 2026-04-28 | SDA-2026-04-28-gap-methodol-20260427-035148-7b3b3df4 |
| h-d3e7e3dd | TREM2-C1Q Competitive Binding to Prevent Complement-Mediated Cholinergic Synapse | 0.59 | 0.60 | TREM2,C1Q | proposed | 2026-04-17 | SDA-2026-04-16-gap-pubmed-20260411-082446-2c1c9e2d |
| h-0516c501 | TFEB Activation to Restore Lysosomal Biogenesis in Aged Synapses | 0.59 | 0.57 | TFEB (TFE3, TFE4 family) | proposed | 2026-04-26 | SDA-2026-04-16-frontier-proteomics-1c3dba72 |
| h-01eb4f1d71 | MALAT1 Three-Way Junction as a Druggable Target for Structure-Selective ASOs | 0.59 | 0.58 | MALAT1 | proposed | 2026-04-21 | SDA-2026-04-10-gap-debate-20260410-075007-232fbf62 |
| h-be57524c3c | Neuronal MHC Class I Expression as a Selectivity Determinant | 0.59 | 0.58 | H2-Kb (H2-K1), Lilrb4 (LilrB2) | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062128-c84a87d9 |
| h-338bb5c155 | Baseline Elevation from ER Stress Is Epiphenomenon, Not Lysosomal Signal Amplifi | 0.59 | 0.52 | PERK,LRRK2 | proposed | 2026-04-26 | SDA-2026-04-23-gap-debate-20260417-033119-54941818 |
| h-412e5c37d3 | Intermittent HBOT (2.0 ATA, 60 min, 3x/week) suppresses NLRP3 inflammasome and s | 0.59 | 0.60 | NLRP3 | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-181340-8acb24dc-debate |
| h-a4fca7bb87 | Peri-plaque tau seeding restraint via TREM2-competent microglia | 0.59 | 0.60 | TREM2 | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-150544-e3a2eab9-debate |
| h-78a93db210 | Direct ISR target engagement likely requires trazodone doses around 150-200 mg/d | 0.59 | 0.68 | EIF2AK3; EIF2S1; ATF4; DDIT3 | proposed | 2026-04-26 | |
| h-0a073f51c0 | A post-trigger CDK5-dominant kinase feedback loop maintains dendritic phospho-ta | 0.59 | 0.63 | MAPT,CDK5,CAPN1,GSK3B | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-98a600b3ed |
| h-663b2136a8 | APOE isoform modifies the C1q binding landscape, biasing C1q toward inflammatory | 0.59 | 0.55 | APOE,C1QA,C1QB,C1QC,TREM2,APP | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-afba1a80bd |
| h-b4b09dedb2 | G3BP1 Haploinsufficiency Reveals a Therapeutic Window for SG-Targeting Intervent | 0.59 | 0.50 | G3BP1 | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041428-e14e6524 |
| h-175225ed30 | Competition with G3BP1-Caprin1/FMRP Scaffold Formation | 0.59 | 0.62 | G3BP1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041423-2d1db50c |
| h-8ffdaff434 | CHIP-mediated ubiquitination selectively targets oligomeric pathologic conformer | 0.59 | 0.58 | STUB1 (CHIP), HSPA8, VCP, PSMD4 | proposed | 2026-04-21 | SDA-2026-04-10-gap-debate-20260410-075012-32bac138 |
| h-47ab2be5 | Multiplexed Base Editing for Simultaneous Neuroprotective Gene Activation | 0.59 | 0.55 | SOD1, TARDBP, BDNF, GDNF, IGF-1 | proposed | 2026-04-04 | SDA-2026-04-03-gap-crispr-neurodegeneration-20260402 |
| h-12cb145d57 | Microglial Replacement and Ontogeny Shift | 0.59 | 0.60 | CCR2 | proposed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062045-56983337 |
| h-d4d93da2 | M1 Muscarinic Receptor Agonism as Pharmacological Exercise Substitute | 0.59 | 0.72 | CHRM1 | promoted | 2026-04-15 | SDA-2026-04-14-gap-pubmed-20260410-191046-15921012 |
| h-var-5aec85b987 | TREM2-Mediated Microglial Dysfunction Disrupts Oligodendrocyte Tau Clearance Net | 0.59 | 0.71 | TREM2 | proposed | 2026-04-12 | SDA-2026-04-03-26abc5e5f9f2 |
| h-cae1ad2e | Astrocyte-Derived EV miR-146a-5p Mimics as Erasers of Trained Microglial NF-κB M | 0.59 | 0.58 | miR-146a-5p → IRAK1, TRAF6, NOTCH1, HDAC1 | proposed | 2026-04-26 | SDA-2026-04-08-gap-debate-20260406-062033-ad87c3fb |
| h-4639c944 | AP1S1-Mediated Vesicular Transport Restoration | 0.59 | 0.60 | AP1S1 | proposed | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-cc1076c1 | Cardiovascular-Neuroinflammation Crosstalk Interruption | 0.59 | 0.50 | IL1B, TNFA, NLRP3 | debated | 2026-04-04 | SDA-2026-04-04-gap-20260404-microglial-priming-early-ad |
| h-var-3891c45d35 | TREM2-Mediated Oligodendrocyte-Microglia Signaling in White Matter Neurodegenera | 0.59 | 0.53 | TREM2 | proposed | 2026-04-21 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-678435d0 | TNFRSF25-Mediated Aging Exosome Pathway Inhibition | 0.59 | 0.45 | TNFRSF25 | proposed | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-9c857387 | TREM2 Signaling Bifurcation with Independent TYROBP-Independent Homeostatic Main | 0.59 | 0.40 | TREM2 | promoted | 2026-04-15 | SDA-2026-04-14-gap-pubmed-20260411-072446-a32fa49c |
| h-6e2ad5b857 | CSF p-tau217 Normalization Reflects Amyloid-Driven Tau Pathology Resolution (Mec | 0.59 | 0.55 | NA - Mechanistic hypothesis | proposed | 2026-04-25 | |
| h-894b633a | REDD1-mTOR Axis as the Master Regulator — Preservation Over Chelation | 0.59 | 0.62 | DDIT4 (REDD1), MTOR | promoted | 2026-04-16 | SDA-2026-04-15-gap-pubmed-20260411-092119-691e1977 |
| h-08a79bc5 | Senescence-Tau Decoupling Therapy | 0.59 | 0.40 | CDKN2A | proposed | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-SDA-2026-04-26-gap | Circadian-Phase Anchored Low-Dose Melatonin for Prevention | 0.59 | 0.43 | MT1/MT2 melatonin receptors; CLOCK/BMAL1 | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260411-090734-1be1b913 |
| h-SDA-2026-04-26-gap | Residual Vascular Amyloid Prevents Complete CSF p-tau217 Normalization, Requirin | 0.59 | 0.36 | APOE, CLU | proposed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260417-033134-20519caa |
| h-e3a48208 | Mitochondrial-Lysosomal Coupling Enhancer | 0.59 | 0.50 | LAMTOR1 | proposed | 2026-04-04 | SDA-2026-04-03-gap-debate-20260403-222617-8eb5bdbc |